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Oral Mucositis and Stomatitis Associated with Conventional and Targeted
Anticancer Therapy
Abstract
Oral mucositis and stomatitis are characterized by pain, inflammation, and redness in the oral cavity. In
the case of mucositis, ulceration also occurs. Despite being understudied, these symptoms are some of
the most troubling, and yet common, adverse effects associated with cancer treatment. The incidence of
these toxicities is highly variable depending on treatment-related and patient-related risk factors.
However, most cancer treatment regimens carry some risk of this toxicity. The presence of mucositis or
stomatitis can result in a significant decrease in the patient?s quality of life due to severe pain and the
inability to eat or drink. These toxicities can also negatively affect the overall outcome of cancer
treatment, leading to dose reductions and delays in treatment. Although the mechanism is not yet
understood, the rapid increase in the number of targeted anticancer therapies available on the market has
increased the number of patients who experience oral toxicities. The toxicities caused by targeted agents
are less severe than those caused by conventional anticancer agents, but due to prolonged dosing
schedules, they can still lead to significant declines in quality of life. The pathobiology of oral mucositis is
a complex five phase process. It involves injury, activation of enzymes and transcription factors,
upregulation of cytokine genes, inflammation/damage to tissue, and healing. These processes not only
involve cells in the oral mucosa, but also the surrounding fibroblasts and connective tissue cells. A better
understanding of the mechanisms behind oral mucositis and stomatitis will facilitate the development of
effective prediction, prevention, and treatment strategies.
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Oral Mucositis and Stomatitis Associated with Conventional and Targeted
Anticancer Therapy
Amy L Parkhill*
St. John Fisher College, Wegmans School of Pharmacy, Rochester, NY, USA

Abstract
Oral mucositis and stomatitis are characterized by pain, inflammation, and redness in the oral cavity. In the
case of mucositis, ulceration also occurs. Despite being understudied, these symptoms are some of the most
troubling, and yet common, adverse effects associated with cancer treatment. The incidence of these toxicities is
highly variable depending on treatment-related and patient-related risk factors. However, most cancer treatment
regimens carry some risk of this toxicity. The presence of mucositis or stomatitis can result in a significant decrease
in the patient’s quality of life due to severe pain and the inability to eat or drink. These toxicities can also negatively
affect the overall outcome of cancer treatment, leading to dose reductions and delays in treatment. Although the
mechanism is not yet understood, the rapid increase in the number of targeted anticancer therapies available on the
market has increased the number of patients who experience oral toxicities. The toxicities caused by targeted agents
are less severe than those caused by conventional anticancer agents, but due to prolonged dosing schedules,
they can still lead to significant declines in quality of life. The pathobiology of oral mucositis is a complex five
phase process. It involves injury, activation of enzymes and transcription factors, upregulation of cytokine genes,
inflammation/damage to tissue, and healing. These processes not only involve cells in the oral mucosa, but also the
surrounding fibroblasts and connective tissue cells. A better understanding of the mechanisms behind oral mucositis
and stomatitis will facilitate the development of effective prediction, prevention, and treatment strategies.

Keywords: Oral mucositis; Stomatitis; Oral toxicities; Chemotherapy;

Targeted cancer therapy

Introduction
It is indisputable that the effective treatment of malignancies is
often limited by the harm inflicted on normal, healthy cells [1]. Given
their high rate of turnover, mucosal cells in the oral cavity are highly
susceptible to the toxic effects of cancer treatment [2]. Toxicities of
the oral cavity, which include mucositis and stomatitis, are some of
the most significant and unavoidable toxicities associated with cancer
treatment [3]. Advances in the ability of anticancer treatment to
damage and kill cancer cells has also led to changes in the incidence,
nature, and severity of oral complications [3]. Cytotoxic chemotherapy
has long been associated with a high risk of oral toxicity. However,
the risk associated with the newer targeted agents is only begun to be
realized. Despite being underreported and often under recognized, oral
toxicities have a tremendous impact on the cancer patient and on the
resources of the healthcare system. For example, oral toxicities are a
common cause of dose delays and interruptions of cancer therapy [4].
Unfortunately, the currently available treatments for oral toxicities are
primarily palliative and in many cases, only marginally effective [57]. The lack of effective treatments and prevention strategies may be
attributed to the fact that research on oral toxicities has lagged behind
research on other chemotherapy and radiation-related toxicities such as
febrile neutropenia and nausea and vomiting [4].

oral mucositis and stomatitis. Clinically, the terms mucositis and
stomatitis are often used interchangeably, but they do not have identical
pathologies [2].
Mucositis is the term describing the lesions caused by anticancer
agents. It can occur to any mucosal cells, but most commonly occurs in
the cells of the oral cavity and small intestine[5]. Oral mucositis caused
by cytotoxic chemotherapy is characterized by painful inflammation,
erythema, swelling, and ulcerations of the oral mucosa in the oral
cavity, oropharynx, and hypopharynx [8,9]. Oral mucositis varies
in intensity from a grade 1 to a grade 4. Grade 1 is characterized by
redness and soreness and grade 4 prevents the patient from ingesting
anything orally (Table 1) [10].
Stomatitis refers to inflammation that occurs in any tissue in the oral
cavity [9]. Therefore, stomatitis includes a broad range of conditions,
including oral mucositis. A majority of the research performed to date
has specifically focused on oral mucositis. However, the increasing use
of targeted anticancer agents (e.g. mammalian target of rapamycin
(mTOR) inhibitors, inhibitors of Epidermal Growth Factor Receptor
(EGFR) signaling, and tyrosine kinase inhibitors) has brought forth the
need to carefully distinguish between the pathology and pathogenesis
of mucositis and stomatitis.

Mucositis and Stomatitis
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The damage inflicted upon the oral cavity by various modalities
of cancer treatment can result in a variety of conditions including
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Oral soreness, erythema

Grade 2

Ulcers, but able to eat solid food

Grade 3

Oral ulcers and able to take liquids only

Grade 4

Oral alimentation impossible

Table 1: World Health Organization Oral Mucositis Scale adapted from [4,10]
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Treatment-related

Patient-related

• Type of medication

• Type of malignancy

• Dose

• Age

• Schedule of medication (e.g.
number of cycles)

• Poor oral health and hygiene

• Route of administration

• Salivary gland dysfunction

• Concomitant radiation therapy

• Body mass index

• Dose and field of radiation

• Gender
• Genetic polymorphisms in drug
metabolizing enzymes[22]and TNF-α [21]
• Co-morbid disease states (e.g. psoriasis,
Addison’s disease, diabetes) [6]

Table 2: Risk factors for oral mucositis adapted from [9,20].

Epidemiology of Oral Mucositis
The incidence and severity of mucositis is highly variable and is
dependent on treatment-related and patient-related risk factors [11]
(Table 2). Currently, treatment-related risk factors are more important
to consider than patient-related factors, and should be assessed
before treatment initiation [4]. Treatment-related risk factors include
type, dose, schedule of chemotherapy, route of administration, and
concomitant use of chemotherapy and radiation [9,12]. Patients who
receive standard-dose chemotherapy has an estimated 40% risk of
all-grade mucositis [13] and the risk of mucositis approaches 100%
in patients with head and neck cancer who receive both intensive
chemotherapy and radiation [4,14]. The overall risk of developing
mucositis and the severity of mucositis positively correlate with the
number of chemotherapy cycles due to increased exposure and the
cumulative damage caused by anticancer agents [3,4].
The reported incidence of mucositis is striking. However, it is
likely what the true incidence of mucositis in clinical practice is much
higher. Currently available knowledge on oral mucositis is derived
from clinical trials. Unfortunately, relatively few clinical trials have
focused on mucositis as a specific outcome and clinical trials often
do not include the full range of patients (e.g. elderly patients, patients
with comorbidities, non-adherent patients) [4]. Additionally, mucositis
often emerges between treatment cycles when clinical monitoring is
sporadic [15].
Although it is difficult to predict whether a patient will develop
mucositis solely based on the class of drug dispensed [2], there are
several drugs that are associated with an increased propensity to damage
the oral mucosa. These drugs include methotrexate, doxorubicin,
5-fluorouracil, busulfan, bleomycin, cisplatin, carboplatin, mTOR
inhibitors, inhibitors of EGFR signaling, and selected tyrosine kinase
inhibitors [2,4,8,16-19].
Most research has focused on treatment-related risk factors, given
the variable response of individual patients to the same treatment
regimen. However, patient-related risk factors also play an important
role in oral toxicity risk [4]. Currently, data is inconclusive pertaining
to the influence of age, gender, body mass index, and nutritional status
on chemotherapy-induced mucositis [4,20]. However, the impact of
genetic factors has become unmistakable. Importantly, differences in
the expression of genes associated with the pathogenesis of mucositis
are common [9]. For example, polymorphisms in the tumor necrosis
factor genes have been shown to increase the risk of toxic lesions [21].
Additionally, although relatively rare, deficiencies in drug metabolizing
enzymes due to genetic polymorphisms have been associated with an
increased risk of methotrexate-induced and 5-fluorouracil-induced
toxicity [22-24].
J Pharmacovigilance
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Impact on Patients
As reported by patients, mucositis is one of the most significant
adverse symptoms of cancer therapy [25,26]. Resources that are needed
to manage the acute effects of mucositis and its impact on the patient
include, but are not limited to: total parental nutrition, increased use
of antifungals and opioid analgesics, increased emergency department
visits, and increased hospitalizations [4,27, 28]. The substantial pain
and ulceration can lead to a decline in oral health, nutritional status,
quality of life, and in severe cases, even death [27,29-31]. The pain
associated with mucositis can persist after treatment is complete and
its management may require parenteral opioid analgesics [32,33].
Unfortunately, opioid analgesics are not always effective in managing
the pain and are associated with aversive side effects such as constipation
and a decrease in alertness [9,25,27]. The pain can also interfere with the
patient’s ability to eat and drink which can lead to weight loss in already
frail patients and required initiation of total parenteral nutrition [26].
The ulcerations in mucositis can create a portal of entry for
pathogens in a patient that may already be immunocompromised due
to myelosuppression [4]. In severe cases, this can lead to life-threatening
systemic infections [34,35]. Research has shown that infection
occurs in 36% of solid tumor patients receiving myelosuppressive
therapy. However, in patients who experience mucositis due to
myelosuppressive therapy, the occurrence of infection increases to 73%
[15]. Unfortunately, these infections may be hard to prevent and predict
because there are no specific criteria for determining risk of infection
during myelosuppression [2].
Mucositis can be considered a dose-limiting toxicity. A reduction
or delay in treatment may be warranted given complications associated
with pain, infection, and inability to eat. As reviewed by Elting et al.
[28], mucositis can lead to a dose reduction of chemotherapy in 23%28% of cycles. These dose reductions are a major source of concern
because they can directly diminish cure rates and patient survival [5].

Pathobiology of Mucositis
The emergence of oral mucositis after intensive chemotherapy
occurs approximately two weeks after chemotherapy initiation [36],
which corresponds to the estimated mitotic rate of oral epithelium of
9 to 16 days [37]. It was previously thought that mucosal toxicity was
simply due to the direct toxicity of chemotherapy agents on mucosal
cells [38]. However, research has determined that the development of
mucositis involves not only the mucosal epithelium, but the submucosa
and the extracellular matrix [39]. The pathobiology follows a discrete five
phase process that includes: 1. Initiation, 2. Signaling, 3. Amplification,
4. Ulceration, and 5. Healing [6,39] (Table 3). An important implication
of this model is that it identifies a variety of potential therapeutic
Phase I –
Initiation

Exposure to chemotherapy or radiation causes generation of
reactive oxygen species (ROS) and lipid peroxidation. This results
in DNA damage and cellular apoptosis

Phase II –
Signaling

ROS cause further damage and stimulate the expression of
NF-κB. NF-κB expression leads to increased production of
proinflammatory cytokines (TNF-α, IL-1β, IL-6)

Release of proinflammatory cytokines leads to prolonged
Phase III –
tissue injury, apoptosis, vascular permeability, and activation of
Amplification
cyclooxygenase-2.
Phase IV –
Ulceration

Ulceration occurs, providing a portal for the entry for colonization
of microorganisms. Bacteria cause activation of macrophages and
further production of proinflammatory cytokines

Phase V –
Healing

Signals from submucosa promote epithelial proliferation and
differentiation
Table 3: The phases of oral mucositis adapted from [6,39].
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targets (e.g. sequesters of free radicals, inhibitors of pro-inflammatory
cytokines) that could hinder or reverse the development of mucositis.
Another interesting aspect of the model is that it demonstrates that
microorganisms are a coincident condition and not a direct cause of
mucositis [6]. In a hamster model of mucositis, the development of
lesions preceded increases in bacterial colonization [6]. Even though
microorganisms may not directly cause mucositis, it is important to
note that the presence of infection can often complicate the diagnosis
and management of oral mucositis [40].

Oral Toxicity Caused by Targeted Anticancer Therapy
The use of targeted agents in the treatment of cancer has recently
exploded and has had a significant positive impact on patient quality
of life and survival rates [1]. Since 2012, 14 agents have been approved
by the U.S. Food and Drug Administration [41]. These agents influence
or inhibit the signaling of many cellular targets including mTOR,
EGFR, vascular endothelial growth factor, hedgehog, human epidermal
growth factor receptor 2, and several tyrosine kinases. This explosion
of targeted agents represents the products of the extensive research that
has occurred in the field of cancer cell biology. However, the presence
and function of some of these targets in normal cells is just beginning
to be understood. Unfortunately therefore, targeted anticancer therapy
can also cause significant toxicity to non-cancer cells.
Mucositis is one of the most commonly reported toxicities of mTOR
inhibitors [42,43], and in some studies, it was the dose-limiting toxicity
[44]. Oral toxicities with other targeted agents, such as the kinase
inhibitors and monoclonal antibodies are less common. Yet studies have
shown a significant incidence of all-grade mucositis with bevacizumab,
erlotinib, sorafenib, and sunitinib [15,43]. The incidence of oral toxicity
associated with targeted agents has been shown to increase as the dose
increases [45]. However, unlike with the conventional anticancer agents,
subsequent cycles of targeted agent therapy can lead to a decrease in the
frequency and severity of oral toxicity [45].
The clinical presentation of targeted agent-induced oral mucositis
is quite different from radiation or chemotherapy-induced mucositis.
Typically, it has a rapid onset (within 5 days) and is of mild to moderate
severity (grade 1-2). The lesions are round and have similar appearance
to aphthous stomatitis (canker sores) [12,46]. Another distinguishing
feature of targeted therapy-induced oral toxicity is that the lesions are
more likely to resolve spontaneously even when treatment is continued
[42]. Given these differences, the toxicities seen with targeted agents
may be better classified as stomatitis, rather than oral mucositis
[12,40,47].
Although the severity of targeted agent-induced oral toxicity is less
severe than that caused by conventional chemotherapy, it may still be
dose-limiting [12,17,19]. Treatment with targeted agents is often longterm and may continue until the cancer has progressed or unacceptable
toxicity occurs. Because many of the targeted agents are taken orally
and are self-administered, the negative impact of targeted therapyinduced oral toxicities on patient adherence and treatment outcomes
is significant [17,48].
The exact mechanism of how targeted agents produce oral toxicities
is likely different than the pathways described for conventional
chemotherapy agents. Recent research done in a clinically relevant
rat model of tyrosine kinase inhibitor-induced diarrhea has identified
that unlike with conventional chemotherapy agents, tyrosine kinase
inhibitors do not cause direct damage to mucosal cells [49]. However,
apart from that, the targeted agent-induced mechanism is not wellJ Pharmacovigilance
ISSN: 2329-6887 JP, an open access journal

understood. This may be due in part because targeted agents are often
given in conjunction or after conventional anticancer therapies have
been given. Therefore, the toxicities of targeted agents can combine
with or accentuate the toxicities of conventional chemotherapy and it
may be difficult to distinguish toxicities solely caused by the targeted
agent.

Future Directions
Recent years have seen an increase in the amount and the momentum
surrounding mucositis research in both clinics and in laboratories.
Unfortunately, anticancer agents are not currently classified based on
their oral mucositis risk [4]. Therefore, strategies for prevention and
treatment are still limited and the majority of currently available studies
have significant weaknesses [9]. For example, there are few studies that
focus on chronic complications and survivorship issues [8]. However,
as cancer survivor rates increase, it becomes important to understand
the impact of mucositis on the long-term oral health and well-being of
the patient [3]. Additionally, given the impact that oral toxicities have
on daily functioning, there is a need for research to focus not only on
the incidence of oral mucositis and stomatitis, but also on the severity
and duration. In order to accomplish this, studies would likely need
to increase monitoring between treatment cycles and also incorporate
patient-reported symptoms with clinical diagnostic tools [15].
The discovery of the complex pathobiology of mucositis has
undeniably created several potential avenues for drug development and
research [6]. However, given the complexity of most cancer treatment
regimens, it will be challenging to manage the toxicities of simultaneous
multiple agents, some of which have an unknown mechanism,
without jeopardizing the ultimate goal of destroying cancer cells [50].
For example, it is possible that the desired treatment effect and the
undesired toxicity are inseparable and that attenuating toxicity will also
lead to reductions in efficacy [51].

Conclusion
As Sonis states, mucositis is toxicity that “largely defies effective
intervention” [12,50]. Now that febrile neutropenia and chemotherapyinduced nausea and vomiting are managed with various pharmacologic
agents, mucositis has become one of the most troubling dose-limiting
toxicities for patients. However, given the tremendous impact that these
oral toxicities have on the patient and the healthcare system, urgent
studies are needed to develop effective strategies for prevention and
treatment.
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